» Articles » PMID: 20146582

Insulinoma: Pathophysiology, Localization and Management

Overview
Journal Future Oncol
Specialty Oncology
Date 2010 Feb 12
PMID 20146582
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Insulinoma is a rare neuroendocrine tumor that causes oversecretion of insulin and, as a result, patients present with symptoms of hypoglycemia. Fortunately, insulinomas are usually benign and solitary, and surgical cure rates are highly favorable. Most of these tumors occur sporadically, but they can also be associated with multiple endocrine neoplasia type-1 syndrome. The diagnosis is confirmed by a supervised fast, and early detection is important. Several preoperative and intraoperative techniques with various success rates have been employed in order to localize the lesion. When technically feasible, tumor enucleation is the procedure of choice; however, a more formal resection may be necessary for certain tumors. In the age of laparoscopy, the role of laparoscopic surgery in the management of insulinomas is continuing to attract attention. This review will discuss the historical background, pathogenesis, diagnosis, localization and management of insulinomas.

Citing Articles

Complete Resolution of Frequent, Non-Specific Hypoglycemia Symptoms After Surgical Removal in a Patient With Pancreatic Tail Insulinoma: A Case Report.

Huda F, Hutajulu S, Aresy S, Pramono R, Barmawi A, Sumpono A Cureus. 2025; 17(1):e77662.

PMID: 39968426 PMC: 11834942. DOI: 10.7759/cureus.77662.


Insulinoma in Patients with Diabetes- A Systematic Review of Previously Reported Cases.

Chatterjee S, Bhattacharjee R, Ghosh R, Chakraborty P, Sinha A, Maiti A Indian J Endocrinol Metab. 2025; 28(6):554-561.

PMID: 39881762 PMC: 11774416. DOI: 10.4103/ijem.ijem_154_24.


Diagnosis and management of benign secreting pancreatic insulinoma: What's new? 4 case report.

Bahou K, Achour Y, Ilahiane M, Sekkat H, Bakali Y, Mhamdi Alaoui M Rare Tumors. 2025; 17():20363613241313409.

PMID: 39790868 PMC: 11713962. DOI: 10.1177/20363613241313409.


Engineered tools to study endocrine dysfunction of pancreas.

Alver C, Dominguez-Bendala J, Agarwal A Biophys Rev (Melville). 2024; 5(4):041303.

PMID: 39449867 PMC: 11498943. DOI: 10.1063/5.0220396.


Intraoperative intermittently scanned continuous glucose monitoring in the management of patients with pancreatic insulinoma.

Magliozzo M, Tumminia A, Arpi M, Deiana E, Guglielmo M, Giannone G J Endocrinol Invest. 2024; 48(3):777-781.

PMID: 39400889 DOI: 10.1007/s40618-024-02472-6.


References
1.
Boukhman M, Karam J, Shaver J, Siperstein A, Delorimier A, Clark O . Localization of insulinomas. Arch Surg. 1999; 134(8):818-22; discussion 822-3. DOI: 10.1001/archsurg.134.8.818. View

2.
Forrer F, Valkema R, Kwekkeboom D, de Jong M, Krenning E . Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 2007; 21(1):111-29. DOI: 10.1016/j.beem.2007.01.007. View

3.
Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M . Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature. 1988; 332(6159):85-7. DOI: 10.1038/332085a0. View

4.
Menegaux F, Schmitt G, MERCADIER M, Chigot J . Pancreatic insulinomas. Am J Surg. 1993; 165(2):243-8. DOI: 10.1016/s0002-9610(05)80519-7. View

5.
Isla A, Arbuckle J, Kekis P, Lim A, Jackson J, Todd J . Laparoscopic management of insulinomas. Br J Surg. 2009; 96(2):185-90. DOI: 10.1002/bjs.6465. View